Literature DB >> 18297532

Early renal injury after myeloablative cord blood transplantation in adults.

Hiroshi Mae1, Jun Ooi, Satoshi Takahashi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Emi Hongo, Seiko Kato, Senji Kasahara, Maki Oiwa-Monna, Yosuke Kurokawa, Arinobu Tojo, Shigetaka Asano.   

Abstract

We report a retrospective analysis of acute renal failure (ARF) in a group of 54 adult patients with hematological malignancies treated with unrelated cord blood transplantation (CBT) after myeloablative conditioning. All patients received four fractionated 12 Gy total body irradiation and chemotherapy as myeloablative conditioning. ARF was defined as the doubling serum creatinine occurring within the first 100 days after CBT. A statistically significant decrement of renal function from baseline was observed in days between 11 and 20. ARF occurred in 27.8% of patients. Although no difference was seen in maximum cyclosporine trough levels, the maximum of vancomycin (VCM) trough levels were significantly higher in patients with ARF (p = 0.01). Our result suggests that it is important to monitor VCM dosing more strictly with pharmacokinetic assessment, especially in days 11 - 20, when the most frequently observed declining renal function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297532     DOI: 10.1080/10428190701824577

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

Review 1.  A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia.

Authors:  Na He; Fei Dong; Wei Liu; Suodi Zhai
Journal:  Infect Drug Resist       Date:  2020-06-16       Impact factor: 4.003

2.  Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review.

Authors:  Juliana Bastoni da Silva; Maria Helena de Melo Lima; Sílvia Regina Secoli
Journal:  Rev Bras Hematol Hemoter       Date:  2014-04-03

Review 3.  Recent Advances of Acute Kidney Injury in Hematopoietic Cell Transplantation.

Authors:  Masahiro Miyata; Kazunobu Ichikawa; Eri Matsuki; Masafumi Watanabe; Daniel Peltier; Tomomi Toubai
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.